Posted by Michael Wonder on 31 Mar 2026
EMA validates indication extension application for Tryngolza (olezarsen) for the treatment of severe hypertriglyceridaemia
30 March 2026 - Sobi today announced that the EMA has validated an indication extension application for Tryngolza (olezarsen) for the treatment of adult patients with severe hypertriglyceridaemia ≥880 mg/dL (≥10 mmol/L).
The submission is supported by results from the pivotal Phase 3 CORE and CORE2 studies, which were published in the New England Journal of Medicine in 2025.
